Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.56 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.52 |
| ▸ | BAD | Q92934 | 1/20 | 0.52 |
| ▸ | TTR | P02766 | 2/20 | 0.46 |
| ▸ | ERN1 | O75460 | 2/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 4/20 | 0.44 |
| ▸ | CA2 | P00918 | 4/20 | 0.44 |
| ▸ | CA12 | O43570 | 3/20 | 0.44 |
| ▸ | CA9 | Q16790 | 3/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.44 |
| ▸ | CA4 | P22748 | 2/20 | 0.44 |
| ▸ | CA6 | P23280 | 2/20 | 0.44 |
| ▸ | CA7 | P43166 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5065165 | 0.83 | BCL2L1 (0.53) | KDM4ELMNAHSD17B10BCL2L1BAD | |
| SCHEMBL26639280 | 0.81 | BCL2L1 (0.52) | KDM4ELMNAHSD17B10BCL2L1BAD | |
| SCHEMBL30585141 | 0.81 | BCL2L1 (0.52) | KDM4ELMNAHSD17B10BCL2L1BAD | |
| SCHEMBL20275806 | 0.81 | ALDH1A1 (0.63) | KDM4ELMNAHSD17B10BCL2L1BAD | |
| SCHEMBL16555872 | 0.80 | SRD5A2 (0.53) | KDM4ELMNAHSD17B10BCL2L1BAD | |
| SCHEMBL9970651 | 0.79 | KDM4E (0.46) | KDM4ELMNAHSD17B10BCL2L1BAD | |
| SCHEMBL19824468 | 0.79 | ALOX5 (0.48) | KDM4ELMNAHSD17B10BCL2L1GAA | |
| SCHEMBL8831992 | 0.78 | ESR1 (0.48) | HSD17B10CA1CA2CA12CA9 | |
| SCHEMBL1513817 | 0.78 | BACE1 (0.52) | KDM4ELMNAHSD17B10BCL2L1GAA | |
| SCHEMBL30694739 | 0.78 | ESR1 (0.48) | HSD17B10CA1CA2CA12CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11827723-B1 | Method for the diimide hydrogenation of emulsified unsaturated polymers | ROCKHILL, ALVIN T. | 2023-11-28 | — | — | US | claimed |
| US-11827723-B1 | Method for the diimide hydrogenation of emulsified unsaturated polymers | ROCKHILL, ALVIN T. | 2023-11-28 | — | — | US | disclosed |
| WO-2019182395-A1 | COMPOUND HAVING NOVEL STRUCTURE, ANTI-INFLAMMATORY AGENT COMPRISING SAME, AND CYCLOOXYGENASE-2 INHIBITOR COMPRISING SAME | 장용민 | 2019-09-26 | — | — | WO | disclosed |
| WO-2019182393-A1 | COMPOUND HAVING NOVEL STRUCTURE, ANTI-INFLAMMATORY AGENT COMPRISING SAME, AND MATRIX METALLOPROTEASE-9 INHIBITOR COMPRISING SAME | 경북대학교 산학협력단 | 2019-09-26 | — | — | WO | disclosed |
| US-20160083336-A1 | FATTY ACID ACYLATED SALICYLATES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. | 2016-03-24 | — | — | US | disclosed |
| EP-2755645-A1 | PHARMACEUTICAL COMBINATIONS INCLUDING ANTI-INFLAMMATORY AND ANTIOXIDANT CONJUGATES USEFUL FOR TREATING METABOLIC DISORDERS | Genmedica Therapeutics SL (ES) | 2014-07-23 | — | — | EP | disclosed |
| WO-2013037985-A1 | PHARMACEUTICAL COMBINATIONS INCLUDING ANTI-INFLAMMATORY AND ANTIOXIDANT CONJUGATES USEFUL FOR TREATING METABOLIC DISORDERS | GENMEDICA THERAPUTICS SL (ES) | 2013-03-21 | — | — | WO | disclosed |
| CN-102470120-A | Ophthalmic solutions for protecting the internal structure of the eyeball against ultraviolet rays or for treating keratoconus with a transepithelial cross-linking technique | SANSEVERINO RENATO | 2012-05-23 | — | — | CN | disclosed |
| WO-2009117584-A2 | ANTI-INFLAMMATORY DRUG DELIVERY SYSTEM | CHAMBERS LYNN (US) | 2009-09-24 | — | — | WO | disclosed |
| US-20070015827-A1 | Methods and compositions for treating ophthalmic conditions via serum retinol, serum retinol binding protein (RBP), and/or serum retinol-RBP modulation | SYTERA, INC. (US) | 2007-01-18 | — | — | US | disclosed |
| US-6900189-B2 | Analgesic and glucosamine compositions | TALLARIDA, RONALD | 2005-05-31 | — | — | US | disclosed |
| EP-1328278-A4 | ANALGESIC AND GLUCOSAMINE COMPOSITIONS | UNIV TEMPLE (US) | 2004-06-16 | — | — | EP | disclosed |
| US-6716417-B2 | Delivery on nonsteroidal antiinflammatory drugs through an inhalation route | ALEXZA MOLECULAR DELIVERY CORPORATION | 2004-04-06 | — | — | US | disclosed |
| EP-1328278-A1 | ANALGESIC AND GLUCOSAMINE COMPOSITIONS | Temple University of the Commonwealth System of Higher Education (US) | 2003-07-23 | — | — | EP | disclosed |
| US-20030000518-A1 | Delivery of nonsteroidal antiinflammatory drugs through an inhalation route | ALEXZA PHARMACEUTICALS, INC. | 2003-01-02 | — | — | US | disclosed |
| US-20020058642-A1 | Analgesic and glucosamine compositions | TEMPLE UNIVERSITY OF THE COMMONWEALTH OF HIGHER EDUCATION | 2002-05-16 | — | — | US | disclosed |
| WO-2002026239-A1 | ANALGESIC AND GLUCOSAMINE COMPOSITIONS | TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2002-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070015827-A1 | Methods and compositions for treating ophthalmic conditions via serum retinol, serum retinol binding protein (RBP), and/or serum retinol-RBP modulation | RBP1, RBP4, ALDH1A2 | KDM4E 3803/4885LMNA 661/4885HSD17B10 844/4885 |
| US-20160083336-A1 | FATTY ACID ACYLATED SALICYLATES AND THEIR USES | FADS1, FASN, ALOX5 | KDM4E 3068/4885LMNA 3266/4885HSD17B10 81/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.